Longitudinal Imaging of Microglial Activation in Different Clinical Variants of Alzheimer's Disease

• Status: Recruiting
• Trial end date: 2025-05-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine how inflammation is related to other changes in the brain that occur during the progression of Alzheimer's disease. The investigators are also studying how inflammation is related to the symptoms that first occur in patients with Alzheimer's disease (AD). For this reason, the investigators are asking people with different versions of Alzheimer's disease to participate. This includes patients with either:

• Posterior cortical atrophy - a version of Alzheimer's disease with vision difficulties

• Logopenic variant primary progressive aphasia - a version of Alzheimer's disease with language difficulties

• Amnestic Alzheimer's disease - a "typical" version of Alzheimer's disease with memory difficulties

• The investigators are also enrolling older adults with normal visual, language, and memory function.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: William Charles Kreisl
• Collaborator: National Institute on Aging (NIA)

Criteria

Inclusion Criteria:

1. Age 50 to 75 years at time of screening.

2. At screening, must have no cognitive impairment, or meet criteria for amnestic Alzheimer's disease, posterior cortical atrophy, or logopenic variant primary progressive aphasia. Diagnoses will be made based on history, exam, neuropsychological testing, brain MRI, and consensus diagnosis.

3. Patients must have Clinical Dementia Rating scale score of 0.5 or 1 at enrollment. Controls must have Clinical Dementia Rating scale score of 0 at enrollment.

4. Subjects unable to provide informed consent must have a surrogate decision maker.

5. Written and oral fluency in English.

6. Able to participate in all scheduled evaluations and to complete all required tests and procedures.

7. In the opinion of the PI, the subject must be considered likely to comply with the study protocol and to have a high probability of completing the study.

Exclusion Criteria:

1. Past or present history of a brain disorder other than Alzheimer's disease (including presence of cortical infarct on MRI even in absence of clinical stroke).

2. Serious medical conditions, which make study procedures of the current study unsafe. Such serious medical conditions include uncontrolled epilepsy and multiple serious injuries.

3. Contraindication to MRI scanning.

4. Conditions precluding entry into the scanners (e.g. morbid obesity, claustrophobia, etc.).

5. Exposure to research related radiation in the past year that, when combined with this study, would place subjects above the allowable limits.

6. Participation in the last year in a clinical trial for a disease modifying drug for AD.

7. Taking immunosuppressive medication (e.g., glucocorticoids, cytostatics, antibodies, drugs acting on immunophilins, interferons, tumor necrosis factor inhibitors). Nonsteroidal anti-inflammatory drugs (NSAIDs) are not exclusionary.